Despite the conflicting results of Fib and cardiovascular outcomes, the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) [27] and Colchicine Cardiovascular Outcomes Trial (COLCOT) [28] did provide encouragement that antiinflammation treatment may be useful in coronary artery disease. Here, FBL is linked to coronary artery disorder.